Lung macrophages play a pivotal role in diseases like idiopathic pulmonary fibrosis. Two types of macrophages—the white blood ...

The UCLA advance opens the door to growing other vascularized organ models, including intestines and colons, providing ...

RAHWAY, NJ, USA I July 02, 2025 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair ...

BMPER attenuated PI3K/AKT signaling and suppressed BMP4-driven smooth muscle activation in models of PAH. BMPER overexpression mitigated the vascular remodeling that characterizes pulmonary arterial ...

Pulmonary arterial hypertension (PAH) is a vascular remodeling disease that pathologically increases pulmonary vascular resistance. Ultimately, this leads to right ventricular failure and ...

251173 Introduction: This study aimed to investigate the characteristics of inflammation-fibrosis coupling in different pulmonary artery hypertension (PAH) types through 18F-labeled fibroblast ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical and outcomes research data on pulmonary arterial hypertension (PAH) to be presented at the ...

Advanced imaging technology can help clinicians better understand pulmonary artery (PA) remodeling and its relation to different types of pulmonary hypertension (PH), according to a new report.

Reston, VA (January 20, 2025)— A new molecular imaging technique— 18 F-FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH ...

Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial Hypertension. Journal of Nuclear Medicine, 2025; 66 (1): 98 DOI: 10.2967/jnumed.124.268376 ...